Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients (Q33783108)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

29 July 2017

Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients (English)

1 reference

Europe PubMed Central

29 July 2017

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

based on heuristic

inferred from title

colorectal carcinoma

1 reference

based on heuristic

inferred from title

author name string

C Montagut

1

1 reference

Europe PubMed Central

29 July 2017

M Iglesias

2

1 reference

Europe PubMed Central

29 July 2017

M Arumi

3

1 reference

Europe PubMed Central

29 July 2017

B Bellosillo

4

1 reference

Europe PubMed Central

29 July 2017

M Gallen

5

1 reference

Europe PubMed Central

29 July 2017

A Martinez-Fernandez

6

1 reference

Europe PubMed Central

29 July 2017

L Martinez-Aviles

7

1 reference

Europe PubMed Central

29 July 2017

I Cañadas

8

1 reference

Europe PubMed Central

29 July 2017

A Dalmases

9

1 reference

Europe PubMed Central

29 July 2017

E Moragon

10

1 reference

Europe PubMed Central

29 July 2017

L Lema

11

1 reference

Europe PubMed Central

29 July 2017

S Serrano

12

1 reference

Europe PubMed Central

29 July 2017

A Rovira

13

1 reference

Europe PubMed Central

29 July 2017

F Rojo

14

1 reference

Europe PubMed Central

29 July 2017

J Bellmunt

15

1 reference

Europe PubMed Central

29 July 2017

J Albanell

16

1 reference

Europe PubMed Central

29 July 2017

language of work or name

0 references

publication date

16 March 2010

1 reference

Europe PubMed Central

29 July 2017

British Journal of Cancer

1 reference

Europe PubMed Central

29 July 2017

102

1 reference

Europe PubMed Central

29 July 2017

7

1 reference

Europe PubMed Central

29 July 2017

1137-1144

1 reference

Europe PubMed Central

29 July 2017

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605612

0 references

EGF receptor in relation to tumor development: molecular basis of responsiveness of cancer cells to EGFR-targeting tyrosine kinase inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853100

4 July 2018

Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853100

4 July 2018

Mitogen-activated protein kinase phosphatase-1 in human breast cancer independently predicts prognosis and is repressed by doxorubicin.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853100

4 July 2018

TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853100

4 July 2018

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853100

4 July 2018

PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853100

4 July 2018

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853100

4 July 2018

Mitogen-activated protein kinase phosphatase-1 modulated JNK activation is critical for apoptosis induced by inhibitor of epidermal growth factor receptor-tyrosine kinase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853100

4 July 2018

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853100

4 July 2018

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853100

4 July 2018

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853100

4 July 2018

DUSP1 is controlled by p53 during the cellular response to oxidative stress

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853100

4 July 2018

Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853100

4 July 2018

Dual-specificity MAP kinase phosphatases (MKPs) and cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853100

4 July 2018

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853100

4 July 2018

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853100

4 July 2018

ERK-dependent MKP-1-mediated cisplatin resistance in human ovarian cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853100

4 July 2018

Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853100

4 July 2018

Cetuximab for the treatment of colorectal cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853100

4 July 2018

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853100

4 July 2018

Role of mitogen-activated protein kinase phosphatases (MKPs) in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853100

4 July 2018

MAP kinase signalling pathways in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853100

4 July 2018

Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853100

4 July 2018

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853100

4 July 2018

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853100

4 July 2018

Mitogen-activated protein kinase phosphatase-1 is required for cisplatin resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853100

4 July 2018

Epidermal growth factor receptor targeting in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853100

4 July 2018

Cooperation of ERK and SCFSkp2 for MKP-1 destruction provides a positive feedback regulation of proliferating signaling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853100

4 July 2018

Oncogenic pathway signatures in human cancers as a guide to targeted therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853100

4 July 2018

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853100

4 July 2018

Evidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an antiapoptotic role

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853100

4 July 2018

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853100

4 July 2018

Mitogen-activated protein kinase phosphatase-1 is overexpressed in non-small cell lung cancer and is an independent predictor of outcome in patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853100

4 July 2018

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853100

4 July 2018

Transcriptional induction of MKP-1 in response to stress is associated with histone H3 phosphorylation-acetylation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853100

4 July 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853100

4 July 2018

The Hallmarks of Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853100

4 July 2018

Reduced MAP kinase phosphatase-1 degradation after p42/p44MAPK-dependent phosphorylation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853100

4 July 2018

Cisplatin induces a persistent activation of JNK that is related to cell death

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853100

4 July 2018

Expression of mitogen-activated protein kinase phosphatase-1 in the early phases of human epithelial carcinogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853100

4 July 2018

Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853100

4 July 2018

The mitogen-activated protein kinase phosphatases PAC1, MKP-1, and MKP-2 have unique substrate specificities and reduced activity in vivo toward the ERK2 sevenmaker mutation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853100

4 July 2018

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605612

21 January 2018

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605612

21 January 2018

ERK1/2 achieves sustained activation by stimulating MAPK phosphatase-1 degradation via the ubiquitin-proteasome pathway

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605612

21 January 2018

PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605612

21 January 2018

PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605612

21 January 2018

KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605612

21 January 2018

Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605612

21 January 2018

p53 Transactivates the phosphatase MKP1 through both intronic and exonic p53 responsive elements

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853100

30 October 2018

Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853100

30 October 2018

CL100/MKP-1 modulates JNK activation and apoptosis in response to cisplatin

1 reference

https://pubmed.ncbi.nlm.nih.gov/20234366

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Targeting tyrosine kinases in cancer: the second wave

1 reference

https://pubmed.ncbi.nlm.nih.gov/20234366

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/20234366

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Targeted therapeutics for cancer treatment: major progress towards personalised molecular medicine

1 reference

https://pubmed.ncbi.nlm.nih.gov/20234366

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

BRAFMutation in Metastatic Colorectal Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20234366

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gastrosplenic fistula from Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605612

7 January 2021

based on heuristic

inferred from DOI database lookup

Moyamoya disease and moyamoya syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605612

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.BJC.6605612

1 reference

Europe PubMed Central

29 July 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

29 July 2017

1 reference

Europe PubMed Central

29 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33783108&oldid=1590513005"